Sun pharmaceutical walk-in on 22th May 2024

Sun pharmaceutical walk-in on 22th May 2024 freshers and Experience for multiple positions.

Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals. Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Vapi, Gujarat, with five psychiatry products and a two-person marketing team. Today it is ranked number one in share of prescriptions with 12 classes of doctors in India and a market leader in Psychiatry, Neurology, Cardiology, Orthopaedics, Gastroenterology, Nephrology, Diabetology, Dermatology, Urology, ENT, Chest and Consulting Physicians . The 2015 acquisition of Ranbaxy made Sun Pharma the largest pharma company in India, the largest Indian pharma company in the US, and the 5th largest specialty generic company globally. Around 70% of Sun Pharma’s revenue is generated from international markets.,. The US and India are the largest markets, accounting for over 60% of the company’s turnover;. Manufacturing is across 43 global locations in India, the US, Asia, Africa, Australia and Europe. In the United States, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. Food and Drug Administration (FDA). Sun Pharma was listed on the stock exchange in 1994 in an issue that was oversubscribed 55 times. The founding family continues to hold a majority stake in the company.

More about company

http://www.sunpharma.com/

Vacancy details –

Department – officer/ Sr officer. production (API) / Apprentice trainee

Qualification – Diploma, BE, B tech chemical , Bsc, Msc, BE

Experience – 0 to 07 years

Salary – not disclosed by recruiter

Similar job’s

Hetero walk-in on 25th May 2024

Sun Pharma has complemented growth with select acquisitions over the last two decades. In 1995, Sun purchased a bulk drug manufacturing plant at Ahmednagar from Knoll Pharmaceuticals and in 1997 acquired MJ Pharma’s dosage plant at Halol. In 1997, Sun Pharma acquired Tamil Nadu Dadha Pharmaceuticals Limited (TDPL) based in Chennai. Also in 1997, Sun Pharma initiated their first foray into the international market with the acquisition of Caraco Pharmaceuticals in North America. In 1998, Sun acquired a number of respiratory brands from Natco Pharma. Other notable acquisitions include Milmet Labs and Cephalexin and 7ADCA actives manufacturing site (1999) Pradeep Drug Company (2000), Phlox Pharma (2004), a formulation plant at Bryan, Ohio and ICN, Hungary from Valeant Pharma and Able Labs (2005), and Chattem Chemicals (2008). In 2010, the company acquired a controlling stake in Taro Pharmaceuticals, amongst the largest generic dermatology companies in the US, with operations across Canada and Israel. In 2012, Sun announced acquisitions of two US companies: DUSA Pharmaceuticals, a dermatology device company; and generic pharma company URL Pharma . In 2014 Sun Pharma entered into a licensing agreement with Merck & Co. Inc. to acquire rights for Tildrakizumab (MK- 3222) for treatment of chronic plaque psoriasis, in order to further strengthen its specialty product pipeline.To access sterile injectable capacity in the US, it acquired Pharmalucence in the US in the same year. In 2015, Sun Pharma acquired Ranbaxy in a US$ 4 billion landmark transaction to become the world’s 5th largest specialty generic pharmaceutical company. In March 2015, Sun Pharma announced it had agreed to buy GlaxoSmithKline’s opiates business in Australia to strengthen its pain management portfolio. The following year Sun Pharma made some significant acquisitions, including 14 prescription brands from Novartis in Japan to enter the Japanese market. It acquired Ocular Technologies, Sarl to strengthen its branded ophthalmic portfolio and also acquired Biosintez to enhance its presence in the Russian market.

Important details –

Location – PANOLI – Gujarat/ Madhuranthagam

Selection process – The selection will be on the basis of interview

Mode of interview – Face to face

Interview rounds of interview – HR

Walk-in interview details –

Date – 22th May 2024 Wednesday

Time – 10:00 Am to 03:00 Pm

Venue – sun pharmaceutical industries Ltd, plot no- 24/2825 phase IV, GIDC industrial estate, PANOLI – 394 116 Dist. Bharuch

Note –

Intrested candidates should carry their updated resume along with photograph, salary supporting with components breakup ( latest incremental letter/ revised salary letter/ appointment letter)